Home › Funds › Rangeley Capital, LLC › ENGN

Rangeley Capital, LLC position in ENGN

ENGENE THERAPEUTICS INC · Health Care

Rangeley Capital, LLC reported holding 287,898 shares of ENGN (ENGENE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$576K, representing 0.80% of its reported portfolio and ranking #41 among its reported holdings. Rangeley Capital, LLC has disclosed ENGN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

Latest position (Q3 2026)287.90K sh
Reported value held$575.80K
Portfolio Weight0.80%
First reportedQ2 2026
Last changeReduce
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Rangeley Capital, LLC's ENGN position evolved

Rangeley Capital, LLC first disclosed a stake in ENGN in Q2 2026 at 305,102 shares (US$528K). The position peaked in Q3 2026 at 287,898 shares, worth US$576K. Across 2 filings, Rangeley Capital, LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 287,898 shares valued at US$576K — a reduction of -17,204 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q2 2026 305.10K $527.83K New
Q3 2026 287.90K $575.80K Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ENGN and 13F data

ENGN (ENGENE THERAPEUTICS INC) is a Health Care company. 23 other funds we track also report a position in ENGN — the largest reported positions include FCPM III SERVICES B.V. (US$19.3M), BML Capital Management, LLC (US$13.3M), ACORN CAPITAL ADVISORS, LLC (US$7.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ENGN

All ENGN fund holders →

FAQ

How long has Rangeley Capital, LLC held ENGN?

Rangeley Capital, LLC has disclosed ENGN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

What is Rangeley Capital, LLC's current position in ENGN?

As of Q3 2026, Rangeley Capital, LLC holds 287.90K shares of ENGN (ENGENE THERAPEUTICS INC), valued at $575.80K, representing 0.80% of its reported portfolio and ranking #41.

Has Rangeley Capital, LLC been buying or selling ENGN?

In the latest 13F filing (Q3 2026), Rangeley Capital, LLC reduced its position in ENGN. The position peaked in Q3 2026 at 287.90K shares.

Which other funds hold ENGN?

Other major institutional holders of ENGN include FCPM III SERVICES B.V., BML Capital Management, LLC, ACORN CAPITAL ADVISORS, LLC, among 23 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.